Vaniqa Related Published Studies
Well-designed clinical trials related to Vaniqa (Eflornithine)
Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. [2007.12.01]
A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. [2007.07]
The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness. [2004.06]
Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. [2000]
Eflornithine versus cotrimoxazole in the treatment of Pneumocystis carinii pneumonia in AIDS patients. [1992.12]
Treatment of recurrent gliomas with eflornithine. [1992.09.16]
Well-designed clinical trials possibly related to Vaniqa (Eflornithine)
The effect of difluoromethylornithine on decreasing prostate size and polyamines in men: results of a year-long phase IIb randomized placebo-controlled chemoprevention trial. [2008.02]
Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention. [2007.08]
Randomized prospective phase III trial of difluoromethylornithine vs placebo in preventing recurrence of completely resected low risk superficial bladder cancer. [2006.08]
Adherence assessment using medication weight in a phase IIb clinical trial of difluoromethylornithine for the chemoprevention of skin cancer. [2005.11]
Results of a phase II double-blinded randomized clinical trial of difluoromethylornithine for cervical intraepithelial neoplasia grades 2 to 3. [2005.01.01]
Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. [2003.03]
A phase II breast cancer chemoprevention trial of oral alpha-difluoromethylornithine: breast tissue, imaging, and serum and urine biomarkers. [2002.10]
Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer. [2002.01]
Phase I chemoprevention study of difluoromethylornithine in subjects with organ transplants. [2001.06]
Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. [2001.05]
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. [2001.01.01]
Chemoprevention of human actinic keratoses by topical 2-(difluoromethyl)-dl-ornithine. [2000.12]
Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. [2000.10]
Incidence of BRCA1/2 germ line alterations in a high risk cohort participating in a phase II chemoprevention trial. [2000.06]
Bayesian monitoring of phase II trials in cancer chemoprevention. [1999.08]
A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. [1998.11]
Phase I chemoprevention study of piroxicam and alpha-difluoromethylornithine. [1998.10]
Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. [1998.08.19]
alpha-difluoromethylornithine ototoxicity. Chemoprevention clinical trial results. [1997.12]
Toxicity evaluation of difluoromethylornithine: doses for chemoprevention trials. [1996.05]
Development of difluoromethylornithine as a chemoprevention agent for the management of colon cancer. [1995]
Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. [1993.05.05]
Urinary polyamine levels in cancer patients treated with D,L-alpha-difluoromethylornithine, an inhibitor of polyamine biosynthesis. [1989.07]
Other research related to Vaniqa (Eflornithine)
Safety and effectiveness of first line eflornithine for Trypanosoma brucei gambiense sleeping sickness in Sudan: cohort study. [2008.03.29]
Eflornithine is a cost-effective alternative to melarsoprol for the treatment of second-stage human West African trypanosomiasis in Caxito, Angola. [2008.02]
A 4-month, open-label study evaluating the efficacy of eflornithine 11.5% cream in the treatment of unwanted facial hair in women using TrichoScan. [2008.01]
Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series. [2007.11.07]
The effect of eflornithine 13.9% cream on the bother and discomfort due to hirsutism. [2007.09]
A randomized bilateral vehicle-controlled study of eflornithine cream combined with laser treatment versus laser treatment alone for facial hirsutism in women. [2007.01.29]
Eflornithine cream combined with laser therapy in the management of unwanted facial hair growth in women: a randomized trial. [2006.10]
Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo. [2006.10]
Excess salt and pepper hair treated with a combination of laser hair removal and topical eflornithine HCl. [2006.06]
Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis. [2005.09.01]
Eflornithine for the treatment of human African trypanosomiasis. [2003.06]
Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. [2002.09]
Percutaneous absorption and pharmacokinetics of eflornithine HCl 13.9% cream in women with unwanted facial hair. [2001.09]
Vaniqa--eflornithine 13.9% cream. [2001.04]
Topical eflornithine. [2001]
Human dermal safety studies with eflornithine HCl 13.9% cream (Vaniqa), a novel treatment for excessive facial hair. [2001]
Phase II trial of recombinant interferon-alpha-2a and eflornithine in patients with recurrent glioma. [1998.01]
The role of the polyamine inhibitor eflornithine in the neuropathogenesis of experimental murine African trypanosomiasis. [1997.06]
A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness. [1997.03]
Eflornithine treatment in SHR: potential role of vascular polyamines and ornithine decarboxylase in hypertension. [1994.09]
Eflornithine concentrations in serum and cerebrospinal fluid of 63 patients treated for Trypanosoma brucei gambiense sleeping sickness. [1993.07]
Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. [1992.09.12]
Eflornithine treatment of refractory Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. [1992.01]
Pneumocystis carinii pneumonia treated with eflornithine in AIDS patients resistant to conventional therapy. [1990.10]
Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. [1990.09]
In vivo effect of eflornithine (DFMO) and some related compounds on Leishmania infantum preliminary communication. [1989.12]
Eflornithine. A new drug in the treatment of sleeping sickness. [1989.06.23]
[African trypanosomiasis in children treated with eflornithine. A case] [1989.06.17]
[A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo] [1989.04]
Intestinal crytosporidiosis treated with eflornithine: a prospective study among patients with AIDS. [1989]
Eflornithine for the treatment of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome: a preliminary review. [1989]
African sleeping sickness in the United States. Successful treatment with eflornithine. [1988.02]
Treatment of human late stage gambiense trypanosomiasis with alpha-difluoromethylornithine (eflornithine): efficacy and tolerance in 14 cases in Cote d'Ivoire. [1987.11]
Treatment of acute myeloid leukemia and blastic phase of chronic myeloid leukemia with combined eflornithine (alpha difluoromethylornithine) and methylglyoxal-bis-guanyl hydrazone (methyl-GAG). [1987]
Other possibly related research studies
Effects of polyamine synthesis inhibitors on primary tumor features and metastatic capacity of human breast cancer cells. [2005]
Suppression and regression of choroidal neovascularization by polyamine analogues. [2005.09]
Karyometry in the early detection and chemoprevention of intraepithelial lesions. [2005.09]
Guidance for the management of hirsutism. [2005.08]
Ornithine decarboxylase, mitogen-activated protein kinase and matrix metalloproteinase-2 expressions in human colon tumors. [2005.05.28]
Polyamine depletion inhibits irradiation-induced apoptosis in intestinal epithelia. [2005.09]
Albumin stimulates cell growth, l-arginine transport, and metabolism to polyamines in human proximal tubular cells. [2005.05]
Colorectal cancer prevention: is an ounce of prevention worth a pound of cure? [2005.02]
The role of polyamines in human cancer: prospects for drug combination therapies. [2004.12]
Lung distribution of the chemopreventive agent difluoromethylornithine (DFMO) following oral and inhalation delivery. [2004.12]
Cellular mechanisms mediating the anti-invasive properties of the ornithine decarboxylase inhibitor alpha-difluoromethylornithine (DFMO) in human breast cancer cells. [2004]
Polyamines and cancer: old molecules, new understanding. [2004.10]
Tissue-based assay for ornithine decarboxylase to identify patients likely to respond to difluoromethylornithine. [2004.11]
Inhibitors of polyamine metabolism: review article. [2004.07]
Protective role of arginase in a mouse model of colitis. [2004.08.01]
Irreversible ototoxicity associated with difluoromethylornithine. [2004.07]
Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. [2004.10]
Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention. [2004]
Prostate intraepithelial neoplasia in Noble rats, a potential intermediate endpoint for chemoprevention studies. [2004.06]
[Clinical reasoning and decision making in practice. A depressive foreign woman with symptoms of malaise] [2004.04.17]
Chemoprevention of cancer of the upper respiratory tract of the Syrian golden hamster by aerosol administration of difluoromethylornithine and 5-fluorouracil. [2004.04.01]
The chemopreventive agent alpha-difluoromethylornithine blocks Ki-ras-dependent tumor formation and specific gene expression in Caco-2 cells. [2004.04]
Retaking sleeping sickness control in Angola. [2004.01]
Review article: chemoprevention of colorectal cancer. [2004.01.01]
Barrett's esophagus: chemoprevention. [2003.07]
Hexachlorobenzene-induced early changes in ornithine decarboxylase and protein tyrosine kinase activities, polyamines and c-Myc, c-Fos and c-Jun proto-oncogenes in rat liver. [2003.12]
Antimalarial effect of agmatine on Plasmodium berghei K173 strain. [2003.09]
Pseudofolliculitis barbae: review and update on new treatment modalities. [2003.07]
Suramin selectively inhibits carcinoma cell growth that is dependent on extracellular polyamines. [2003.03]
Current chemotherapy of human African trypanosomiasis. [2003.06]
Inhibition of the development of metastatic squamous cell carcinoma in protein kinase C epsilon transgenic mice by alpha-difluoromethylornithine accompanied by marked hair follicle degeneration and hair loss. [2003.06.15]
Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. [2003.05]
The evaluation and management of hirsutism. [2003.05]
Chemoprevention of prostate carcinogenesis by DFMO and/or finasteride treatment in male Wistar rats. [2002.11]
Polyamine biosynthesis inhibition enhances HSV-1 thymidine kinase/ganciclovir-mediated cytotoxicity in tumor cells. [2003.04.10]
[The return of sleeping sickness in an epidemic form: international action for drugs] [2002.12.28]
Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line. [2003.01.14]
Removal of unwanted facial hair. [2002.11.15]
|
